摘要:
The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
摘要:
The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
摘要:
The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
摘要:
The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
摘要:
The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
摘要:
The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
摘要:
The present invention relates to several new, polymorphous crystal forms of Dicyclanil, and hydrates and solvates thereof, as well as the preparation thereof. In particular, the invention relates to substantially pure crystal forms of Dicyclanil, having characteristic lattice structures, which are effective for the control of insects and ectoparasites.
摘要:
Novel crystal modifications of (+)-catechin monohydrate and of (+)-catechin anhydrate more suitable for pharmaceutical preparations for reasons of higher stability against moisture and/or light and distinguished from hitherto known modifications by unique X-ray diffraction spectra are produced by specific recrystallization and/or crystal rearrangement processes and pharmaceutical preparations comprising the novel crystal forms.
摘要:
The present invention provides a hydrate of the 4,4′-di-triazinylamino-2,2′-di-sulfostilbene compound having the formula: in which M and M1 independently represent hydrogen, an alkaline-, an alkaline earth metal or ammonium, x is a number within the range of from 1 to 30, and the crystal form of the hydrate (I) being characterised by an X-ray diffraction pattern which is essentially as set out in the accompanying FIGS. 1 to 11; or a mixture containing one or more of the hydrates of the 4,4′-di-triazinylamino-2,2′-di-sulfostilbene compound having the formula (I); processes for the preparation of the new hydrates; and the use of the new hydrates for the preparation of concentrated aqueous formulations of fluorescent whitening agents.
摘要:
The present invention provides a hydrate of the 4,4'-di-triazinylamino-2,2'-di-sulfostilbene compound having the formula: ##STR1## in which M and M.sub.1 independently represent hydrogen, an alkaline-, an alkaline earth metal or ammonium, x is a number within the range of from 1 to 30, and the crystal form of the hydrate (I) being characterized by an X-ray diffraction pattern which is essentially as set out in the accompanying FIGS. 1 to 11; or a mixture containing one or more of the hydrates of the 4,4'-di-triazinylamino-2,2'-di-sulfostilbene compound having the formula (I); processes for the preparation of the new hydrates; and the use of the new hydrates for the preparation of concentrated aqueous formulations of fluorescent whitening agents.